Cover Image
市場調查報告書

高磷酸鹽血症治療藥的全球市場 - 2015∼2019年

Global Hyperphosphatemia Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 247833
出版日期 內容資訊 英文 89 Pages
訂單完成後即時交付
價格
Back to Top
高磷酸鹽血症治療藥的全球市場 - 2015∼2019年 Global Hyperphosphatemia Drugs Market 2015-2019
出版日期: 2015年08月12日 內容資訊: 英文 89 Pages
簡介

高磷酸鹽血症治療藥的全球市場預計從2014年到2019年這段期間將以10.71%的年複合成長率(CAGR)持續成長。

本報告涵蓋高磷酸鹽血症治療藥的全球市場,詳細調查推動市場成長要素,市場課題,市場趨勢,以及市場競爭狀況,再基於業許多專家提供的資料和資訊,進行目前市場方案分析以及2015年到2019年的市場成長預測。

第1章 摘要整理

第2章 本報告涵蓋範圍

  • 市場概要
  • 頂級供應商的產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 產品簡介

第5章 序論

  • 市場相關資料的重要事項

第6章 疾病概要

  • 高磷酸鹽血症的把握
  • 病因
  • 高磷酸鹽血症的影響
  • 原因
  • 徵兆及症狀
  • 診斷
  • 治療
  • 流行病學

第7章 高磷酸鹽血症治療方法的發達

第8章 磷酸粘合劑使用的指南

  • CKD (慢性腎臟病) 階段 2∼4
  • CKD 階段 5

第9章 醫藥品開發分析

  • 醫藥品候補相關資訊

第10章 市場概況

  • 市場概要
  • 市場規模及未來預測
  • 波特的五力分析

第11章 高磷酸鹽血症治療的市場動態

第12章 服用型態別市場分類

  • 固態
  • 液狀

第13章 製劑成分別市場分類

  • 鋁性磷酸粘合劑
  • 鈣性磷酸粘合劑
  • 非鋁·非鈣性磷酸粘合劑
  • 鎂性磷酸粘合劑
  • 鐵性磷酸粘合劑

第14章 各地區市場分類

  • 高磷酸鹽血症治療藥全球市場的各地區分類
  • 南北美洲地區的高磷酸鹽血症治療藥市場
  • 歐洲·中東·非洲地區的高磷酸鹽血症治療藥市場
  • 亞太地區的高磷酸鹽血症治療藥市場

第15章 主要國家

  • 主要國家
  • 美國的高磷酸鹽血症治療藥市場
  • 日本的高磷酸鹽血症治療藥市場

第16章 推動市場成長要素

第17章 推動市場成長要素和那個的影響

第18章 市場課題

第19章 推動市場成長要素和市場課題帶來的影響

第20章 市場趨勢

第21章 供應商情形

  • 市場競爭方案
  • 市場佔有率分析 - 2014年
  • 品牌的差異化
  • 其他卓越供應商

第22章 主要供應商分析

  • Fresenius Medical Care
  • Keryx Biopharmaceuticals
  • Sanofi
  • Shire
  • Vifor Pharma

第23章 附錄

第24章 關於Technavio

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR6991

About hyperphosphatemia

Phosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulting in high levels of phosphate in the blood causes hyperphosphatemia. Individuals with chronic kidney diseases have a decreased glomerular filtration rate and increased serum phosphate levels. The high phosphate levels in the serum lower calcium levels because of phosphate precipitation by calcium ions, leading to calcification of vascular tissues and heart diseases. Aluminum-, calcium-, magnesium-, and iron-based and aluminum-free, calcium-free phosphate binders are used to treat the condition.

Technavio's analysts forecast the global hyperphosphatemia drugs market to grow at a CAGR of 10.71% over the period 2014-2019.

Covered in this Report

In this report, Technavio covers the present scenario and growth prospects of the global hyperphosphatemia drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of branded, generic, OTC, and off-label drugs used for treating hyperphosphatemia.

Technavio's report, Global Hyperphosphatemia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hyperphosphatemia drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Fresenius Medical Care
  • Keryx Biopharmaceuticals
  • Sanofi
  • Shire
  • Vifor Pharma

Other Prominent Vendors

  • Alkem
  • Amgen
  • Ardelyx
  • AstraZeneca
  • Baxter
  • Bayer
  • Chugai Pharmaceutical
  • Japan Tobacco
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • Mylan
  • Natco
  • Novartis
  • Opko Health
  • Panion & BF Biotech
  • Roxane Laboratories
  • Sandoz
  • Synthon
  • Torri Pharmaceutical

Market driver

  • Increased number of people undergoing dialysis
  • For a full, detailed list, view our report

Market challenge

  • Non-adherence to treatment regimens
  • For a full, detailed list, view our report

Market trend

  • Patient assistance programs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Product profiles

PART 05: Introduction

  • Key market highlights

PART 06: Disease Overview

  • Understanding the disease
  • Etiology
  • Effects of hyperphosphatemia
  • Causes
  • Signs and symptoms
  • Diagnosis
  • Management
  • Epidemiology

PART 07: Key developments in hyperphosphatemia therapy

PART 08: Guidelines for use of phosphate binders

  • CKD stages 2-4
  • CKD stage 5

PART 09: Pipeline analysis

  • Information on pipeline candidates

PART 10: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 11: Hyperphosphatemia management market dynamics

PART 12: Market segmentation by dosage form

  • Solid
  • Liquid

PART 13: Market segmentation by formulation

  • Aluminum-based phosphate binders
  • Calcium-based phosphate binders
  • Aluminum-free, calcium-free phosphate binder
  • Magnesium-based phosphate binders
  • Iron-based phosphate binders

PART 14: Geographical segmentation

  • Global hyperphosphatemia drugs market segmentation by geography
  • Hyperphosphatemia drugs market in Americas
  • Hyperphosphatemia drugs market in EMEA
  • Hyperphosphatemia drugs market in APAC

PART 15: Key leading countries

  • Key leading countries
  • Hyperphosphatemia drugs market in the US
  • Hyperphosphatemia drugs market in Japan

PART 16: Market drivers

PART 17: Impact of drivers

PART 18: Market challenges

PART 19: Impact of drivers and challenges

PART 20: Market trends

PART 21: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Brand differentiation
  • Other prominent vendors

PART 22: Key vendor analysis

  • Fresenius Medical Care
  • Keryx Biopharmaceuticals
  • Sanofi
  • Shire
  • Vifor Pharma

PART 23: Appendix

  • List of abbreviation

PART 24: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Pathophysiology of hyperphosphatemia
  • Exhibit 03: Effects of hyperphosphatemia
  • Exhibit 04: Differential diagnosis of hyperphosphatemia
  • Exhibit 05: Ideal characteristics of phosphate binders
  • Exhibit 06: Advantages and disadvantages of different phosphate binders
  • Exhibit 07: Prevalence of CKD among participants by CKD stage in US 1988-2012
  • Exhibit 08: Number of dialysis patients worldwide 2012-2014 (millions)
  • Exhibit 09: Pipeline portfolio of hyperphosphatemia drugs
  • Exhibit 10: Global hyperphosphatemia drugs market 2014-2019 ($ millions)
  • Exhibit 11: Five forces analysis
  • Exhibit 12: Market dynamics of phosphate binders for hyperphosphatemia
  • Exhibit 13: Segmentation of global hyperphosphatemia drugs market by dosage form
  • Exhibit 14: Segmentation of global hyperphosphatemia drugs market by formulation
  • Exhibit 15: Global hyperphosphatemia drugs market segmentation by geography 2014
  • Exhibit 16: Global hyperphosphatemia drugs market segmentation by geography 2014-2019 ($ millions)
  • Exhibit 17: Hyperphosphatemia drugs market in Americas 2014-2019 ($ millions)
  • Exhibit 18: Hyperphosphatemia drugs market in EMEA 2014-2019 ($ millions)
  • Exhibit 19: Hyperphosphatemia drugs market in APAC 2014-2019 ($ millions)
  • Exhibit 20: Hyperphosphatemia drugs market in the US 2014-2019 ($ millions)
  • Exhibit 21: Hyperphosphatemia drugs market in Japan 2014-2019 ($ millions)
  • Exhibit 22: Number of individuals who underwent dialysis by region 2012-2014
  • Exhibit 23: Percentage of individuals who underwent dialysis by region 2012-2014
  • Exhibit 24: Global prevalence of diabetes 2014 and 2035 (millions)
  • Exhibit 25: Worldwide population aged 80 and above 1950-2050 (millions)
  • Exhibit 26: Impact of drivers
  • Exhibit 27: Rate of adherence to phosphate binders
  • Exhibit 28: Impact of drivers and challenges
  • Exhibit 29: R&D expenses by Auryxia 2012-2014 ($)
  • Exhibit 30: Global hyperphosphatemia market share analysis 2014
  • Exhibit 31: Ranking of vendors in market
  • Exhibit 32: Sanofi: YoY growth and revenue of Renagel and Renvela 2011-2014 ($ millions)
  • Exhibit 33: Sanofi: Revenue of Renagel and Renvela by region 2011-2014 ($ millions)
  • Exhibit 34: FOSRENOL: YoY growth and revenue of FOSRENOL except Japan 2011-2014 ($ millions)
  • Exhibit 35: Brand differentiation of phosphate binders by major vendors
  • Exhibit 36: Fresenius: Business segmentation by revenue 2014
  • Exhibit 37: Fresenius: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 38: Fresenius: Geographical segmentation by revenue 2014
  • Exhibit 39: Sanofi: Business segmentation 2014
  • Exhibit 40: Sanofi: Business segmentation by revenue 2014
  • Exhibit 41: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 42: Sanofi: Geographical segmentation by revenue 2014
  • Exhibit 43: Shire: Product segmentation by revenue 2014
  • Exhibit 44: Shire: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 45: Shire: Geographical segmentation by revenue 2014
  • Exhibit 46: Vifor Pharma: Product segmentation
Back to Top